Admedus (ASX:AHZ) could have the highly anticipated interim results available for its Phase 2 clinical study for a Herpes Simplex Virus (HSV-2) therapeutic vaccine in the coming weeks.
HSV-2 is the major causative agent of genital herpes and further positive trial results would provide a boost to infected individuals and to the commercialisation potential of the vaccine.
The economic burden of genital HSV infection and resulting complications is estimated to be greater than $1 billion annually in the U.S. alone.
Further HSV-2 study data is expected to be released during 2016.
The HSV-2 Phase II study had 40 study participants and each study participant will receive either the vaccine or a placebo. The vaccine is initially given as a 3 injection vaccination program, four weeks apart, plus study participants will also receive another injection, a ‘booster’ as it were, 6 months after the last of the 3 vaccinations.
The study is designed to examine the safety of the HSV-2 vaccine in people with HSV-2 as well as look at its ability to stimulate an immune response against the virus.
The Company and the clinical study investigators remain blinded to the study data in accordance with standard clinical study procedures to protect the integrity of the results.
Inventor Professor Ian Frazer's company developed the next generation technology and is now majority controlled by Admedus.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.